ticlopidine has been researched along with Active Hyperemia in 3 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clopidogrel reduces long-term ischemic events in patients with acute coronary syndrome or stable angina (SA) undergoing percutaneous coronary intervention (PCI)." | 7.77 | Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. ( Barbato, E; Bartunek, J; Cuisset, T; De Bruyne, B; Dierickx, K; Hamilos, M; Mangiacapra, F; Meeus, P; Muller, O; Ntalianis, A; Sarno, G; Trana, C; Wijns, W, 2011) |
| "Clopidogrel reduces long-term ischemic events in patients with acute coronary syndrome or stable angina (SA) undergoing percutaneous coronary intervention (PCI)." | 3.77 | Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. ( Barbato, E; Bartunek, J; Cuisset, T; De Bruyne, B; Dierickx, K; Hamilos, M; Mangiacapra, F; Meeus, P; Muller, O; Ntalianis, A; Sarno, G; Trana, C; Wijns, W, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dahmus, JD | 1 |
| Bruning, RS | 1 |
| Kenney, WL | 1 |
| Alexander, LM | 1 |
| Salimi, S | 1 |
| Lewis, JP | 1 |
| Yerges-Armstrong, LM | 1 |
| Mitchell, BD | 1 |
| Saeed, F | 1 |
| O'Connell, JR | 1 |
| Perry, JA | 1 |
| Ryan, KA | 1 |
| Shuldiner, AR | 1 |
| Parsa, A | 1 |
| Hamilos, M | 1 |
| Muller, O | 1 |
| Ntalianis, A | 1 |
| Trana, C | 1 |
| Bartunek, J | 1 |
| Sarno, G | 1 |
| Mangiacapra, F | 1 |
| Dierickx, K | 1 |
| Meeus, P | 1 |
| Cuisset, T | 1 |
| De Bruyne, B | 1 |
| Wijns, W | 1 |
| Barbato, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacogenomics of Anti-Platelet Interventions (The PAPI Study)[NCT00799396] | Phase 4 | 682 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Baseline minus post clopidogrel/pre-aspirin platelet rich plasma (PRP) maximum aggregation. (NCT00799396)
Timeframe: Measured at baseline, and after clopidogrel treatment
| Intervention | percentage of maximum aggregation change (Mean) | |
|---|---|---|
| PRP ADP 20 | PRP Collagen 5 | |
| Overall Study | 38.51 | 14.06 |
Baseline minus post clopidogrel/post-aspirin platelet rich plasma (PRP) maximum aggregation (NCT00799396)
Timeframe: Measured at baseline, and after clopidogrel plus aspirin treatment
| Intervention | percentage of max aggregation change (Mean) | |
|---|---|---|
| PRP ADP 20 | PRP Collagen 5 | |
| Overall Study | 41.21 | 56.64 |
2 trials available for ticlopidine and Active Hyperemia
| Article | Year |
|---|---|
Oral clopidogrel improves cutaneous microvascular function through EDHF-dependent mechanisms in middle-aged humans.
Topics: Administration, Oral; Analysis of Variance; Aspirin; Biological Factors; Blood Flow Velocity; Clopid | 2013 |
Clopidogrel Improves Skin Microcirculatory Endothelial Function in Persons With Heightened Platelet Aggregation.
Topics: Adult; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Endothelium, Vascular; Female; Genotype; Healthy | 2016 |
1 other study available for ticlopidine and Active Hyperemia
| Article | Year |
|---|---|
Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Disease; Endothelium, Vascular; Female; | 2011 |